Tag: Cimerli
Sandoz finalizes the purchase of Cimerli in advance – 03/04/2024 at 09:46
(AOF) – Sandoz (+0.72% to 28.15 Swiss francs), a major player in generic and biosimilar drugs, announces that it has finalized the acquisition of the American biosimilar Cimerli (ranibizumab-eqrn) from…
Sandoz: acquisition of Cimerli finalized
(CercleFinance.com) – Sandoz indicates that it has finalized, ahead of schedule, the acquisition of the American biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, in accordance with the agreement last January for…
Coherus expected to rise sharply after the sale of its drug Cimerli to Sandoz – 01/22/2024 at 2:19 p.m.
(AOF) – Coherus BioSciences is expected to rise sharply after announcing today an agreement to sell its Cimerli (ranibizumab-eqrn) ophthalmology franchise to the Sandoz group for an initial amount of…